Home Control’s Orbiva Signs Strategic MOU with Indonesia’s Articura to Advance Localized Healthcare AI and AIoT Digital Health Ecosystem
HONG KONG, July 27, 2026 /PRNewswire/ -- Home Control International Limited ("Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747) is pleased to announce that its wholly-owned subsidiary, Orbiva Limited ("Orbiva"), has entered into a strategic cooperation memorandum (the "MOU") with PT Articura Tech Indonesia ("Articura"), an Indonesian health technology company, on 23 July...
VARON Highlights Healthy Breathing Habits and the Return of Its Popular Lung Breathing Trainers
Two of VARON's best-selling breathing trainers are back in stock, rounding out an at-home respiratory support lineup that pairs daily breathing exercises with the company's oxygen concentrators. LOS ANGELES, July 27, 2026 /PRNewswire/ -- As more people prioritize respiratory wellness, simple breathing exercises have become an accessible way to support healthy breathing habits and respiratory muscle training. Whether...
IHH Healthcare Expands ‘IHH Catalyst’ to North Asia to Accelerate Clinical Adoption of Healthcare Innovation
Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA LUMPUR, Malaysia, July 27, 2026 /PRNewswire/ -- IHH Healthcare ("IHH"), the world's leading multinational...
Seaweed extract shown to relieve prostate symptoms
In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical trial evaluated the effects of fucoidan, a naturally occurring compound found in...
International Self-Care Day: Dimora Medical Highlights Wound Care as an Essential Part of Everyday Self-Care
NEW YORK, July 25, 2026 /PRNewswire/ -- As International Self-Care Day draws attention to the importance of maintaining health around the clock, the concept of 24/7 self-care continues to gain momentum among consumers seeking more proactive approaches to everyday well-being. While nutrition, exercise, and sleep are often seen as the cornerstones of self-care, effective wound management is another...
Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of its lead asset, LAM561, in...
ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clinical trial has now entered the follow‑up phase. ...
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 24, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended June 30, 2026 (the...
Fapon Showcases AI-Engineered Enzymes and Alzheimer’s Solutions at ADLM 2026, Reinforcing North American Commitment
ANAHEIM, Calif., July 24, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider with deepening roots in North America, will exhibit at ADLM 2026 from July 26 to 30 in Anaheim, California. The company will introduce novel AI-engineered enzymes for molecular diagnostics alongside a full suite of raw materials and blood-based...
AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed...
